Verrica Pharmaceuticals Q3 net loss widens year-over-year to $12.41 million
VRCA•Verrica Pharmaceuticals’ third-quarter 2026 net loss widened to $12.41 million, while revenue fell 52% to $6.91 million. U.S. YCANTH revenue rose 58% to $5.7 million, and the company expects pivotal common-warts trial results in the first quarter and middle of 2027.
1. Quarterly results and outlook
Verrica Pharmaceuticals’ third-quarter 2026 net loss widened year-over-year to $12.41 million, while revenue fell 52% to $6.91 million. U.S. YCANTH product revenue rose 58% to $5.7 million, while research and development expenses more than tripled to $7.58 million, primarily due to higher common-warts program costs; topline results from two pivotal trials are expected in the first quarter of 2027 and mid-2027, respectively.
2. Cash runway
Verrica said access to the remaining $15 million under its credit facility is expected to extend its cash runway into the fourth quarter of 2027.
